Real-world data show TRD costs spike during resistant episodes; Compass’ psilocybin COMP360 delivers durable symptom relief through 26 weeks, potentially easing resource strain.
|Articles|August 23, 2022
Figures for Interest Grows in Treatment of Mood Disorders by Classic Psychedelics
This is the extra table for "Interest Grows in Treatment of Mood Disorders by Classic Psychedelics."
Advertisement
Advertisement
Related to this article
When an antidepressant seems to stop working, the patient’s deterioration is real. The explanation may be less certain.
Adjustment disorder often goes undiagnosed after major life stressors, especially in cancer care; learn updated criteria, risks, and emerging therapies like psilocybin.
Athletes can feel the relief a substance gives them long before they can see what it costs. A composite case of cannabis use in a track athlete shows how to assess both.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Psych Consult: TSH Testing in New-Onset Depression. An Endocrinologist’s Guidance for Psychiatrists
2
ADHD Medications for Managing Menopausal Brain Fog: Improvements in Subjective Executive Function
3
New Phase 2 Data on Bezisterim for the Treatment of Long COVID
4
When Antidepressants Stop Working: Understanding Tachyphylaxis in Clinical Practice
5